secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-085894
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune Q1 net loss $42.3M; CERPASS trial hits 180-patient enrollment target
------------------------------------------------------------------------------

- Cash & short-term investments $395.1M as of June 30, 2022, vs $395.7M at March 31, 2022.
- Net loss $42.3M for Q1 ended June 30, 2022, up from $27.3M year-over-year; R&D expenses rose to $29.5M.
- CERPASS registration trial for RP1 in CSCC reached target enrollment of 180 patients; primary data expected H1 2023.
- First 75 patients enrolled in IGNYTE anti-PD1 failed melanoma cohort; data snapshot with 6-month follow-up expected Q4 2022.
- Phase 2 development program for RP2/3 in SCCHN, HCC, and CRC expected to initiate Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922085894/0001104659-22-085894-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465922085894/tm2222536d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-085894

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer